The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Leap Therapeutics Shares Skip Higher on Positive Preliminary Data From Gastric Cancer Study

  ()
Shares of Leap Therapeutics Inc. traded 38% higher after the company reported positive preliminary data from the Phase 2a DisTinGuish Study of DKN-01 plus tislelizumab at the ESMO Congress. read more >

French Biotech Firm Initiates Pivotal Phase 3 Study of Lanifibranor in 900 NASH Patients

Research Report
  ()
ROTH Capital Partners LLC advised in a research report that Inventiva S.A. has initiated enrollment in its highly anticipated pivotal Phase 3 Study of Lanifibranor in individuals diagnosed with nonalcoholic steatohepatitis. ROTH rates Inventiva a "Buy" with a 12-month price target of €55/share which represents a nearly four-fold increase over the current share price. read more >

Instil Bio Receives FDA Approval to Initiate Expanded Phase 2 Advanced Melanoma Study

  ()
Shares of Instil Bio Inc. traded 16% higher after the company reported it received IND clearance from the U.S. FDA to initiate a Phase 2 clinical trial in advanced melanoma patients. read more >

Biopharma Co. Posts Positive Objective Response & Disease Control Rates in Ovarian Cancer Studies

Research Report
  ()
H.C. Wainwright & Co. advised in a research report that updated data from Mersana Therapeutics Inc.'s expansion study supports its UPLIFT Study and will provide the basis for a new Phase 3 study in 2022. H.C. Wainwright rates Mersana a "Buy" with a target price of $28.00/share. read more >

aTyr Pharma's Fusion Protein Achieves Consistent Dose Response in Pulmonary Sarcoidosis Trial

  ()
Shares of aTyr Pharma Inc. traded 48% higher after the firm reported its ATYR1923 produced positive results in a Phase 1b/2a clinical study by demonstrating consistent favorable dose responses in pulmonary sarcoidosis patients. read more >

Sanofi Makes US$1.9 Billion Offer to Buy Kadmon Holdings to Solidify Its Transplant Business

  ()
Shares of Kadmon Holdings Inc. traded 70% higher after the firm reported it agreed to be acquired by Sanofi SA for $9.50 per share in cash. Sanofi aims to strengthen its transplant business with the addition of Kadmon's Rezurock™ (belumosudil), an FDA-approved, first-in-class treatment for patients 12 years and older with chronic graft-versus-host disease. read more >

Adaptimmune Partners With Genentech to Develop & Market Cancer-Targeted Allogeneic T-Cell Therapies

  ()
Adaptimmune Therapeutics Plc. shares traded 33% higher after the firm reported it formed a strategic partnership with Genentech to develop several "off-the-shelf" and advanced personalized cancer-targeting allogeneic T-cell therapies. read more >

Impel NeuroPharma Gains FDA Approval for First Therapeutic to Deliver DHE to Vascular-Rich Upper Nasal Space for Migraine Treatment Using POD Tech

  ()
Shares of Impel NeuroPharma Inc. traded to a new 52-week high after the company reported that the U.S. Food and Drug Administration has approved TRUDHESA™ (dihydroergotamine mesylate), a patient friendly nasal spray that delivers rapid relief and treatment for acute migraine. read more >

AC Immune Shares Rise 16% After Phase 2 Alzheimer's Trial Data Shows Significant Reductions in Cognitive Decline

  ()
AC Immune SA shares set a new 52-week intraday high after the company reported positive cognitive results for tau-targeting monoclonal antibody semorinemab in a clinical study of patients with mild-to-moderate Alzheimer's disease. read more >

Biopharma's Antibody Approved as Hodgkin's Lymphoma Treatment in China

Research Report
  ()
"This marks the first regulatory approval of an OmniAb antibody discovery engine-derived antibody since Ligand Pharmaceuticals first acquired the technology in 2016," noted an H.C. Wainwright & Co. report. read more >

Israeli Biopharma Advances Five Drug Candidate Trials in Q2/21

Research Report
  ()
The progress Can-Fite BioPharma made with these studies is briefly summarized in a Dawson James Securities report. read more >

Poseida Shares Point Higher After FDA Clears NDA for Relapsed/Refractory Multiple Myeloma Treatment Candidate

  ()
Shares of Poseida Therapeutics traded 10% higher after the company reported that the U.S. Food and Drug Administration granted clearance for its Investigational New Drug Application for P-BCMA-ALLO1, an allogeneic CAR-T candidate for use in treating relapsed/refractory multiple myeloma. read more >

Bolt Bio Partners With Innovent Biologics to Create Three New Cancer Treatments

  ()
Shares of Bolt Biotherapeutics Inc. traded nearly 10% higher after the company reported it is collaborating with Innovent Biologics to develop three new oncology Boltbody™ ISAC programs. read more >

With November PDUFA Date, FDA Could Approve Biotech's Lead Cell Therapy Soon

Research Report
  ()
A BTIG report noted that Legend Biotech's cilta-cel has the potential "to take significant market share within the relapsed-refractory multiple myeloma market and establish a best-in-class profile." read more >

Biopharma's Amino Acid Compound Shows Anti-Inflammatory Effect

Research Report
  ()
Studies suggest that Galmed Pharmaceuticals' Amilo-5MER has "therapeutic potential in a number of inflammatory diseases," according to an H.C. Wainwright & Co. report. read more >

Specialty Pharma's Q2/21 Results 'Fundamentally Ahead of Expectations'

Research Report
  ()
A ROTH Capital Partners report noted that Assertio Therapeutics' business model is starting to gain traction. read more >

Trillium Receives US$2.26B Buyout Bid, Shares Trade 190% Higher

  ()
Trillium Therapeutics shares traded 190% higher after the company reported it agreed to be acquired by pharmaceutical giant Pfizer Inc. for $18.50 per share in cash. read more >

Platform Therapeutics Co. Posts Positive Revenue Surprise in Q2 on Higher Dermatology Product Sales

Research Report
  ()
Dawson James Securities Inc. stated in a research update that Fortress Biotech Inc.'s dermatology business shows good growth potential and helped drive a positive revenue surprise in Q2/21. Dawson James has a "Buy" rating on the stock but noted that the real opportunity for the company lies with its vast pipeline and partnerships, which offer real upside potential. read more >

Biotech Offering Significant Return Potential Advances Lead Breast Cancer Trials

Research Report
  ()
An H.C. Wainwright & Co. report noted Oncolytics Biotech's overall pelareorep program is on track with several near-term catalysts expected. read more >

Global Specialty Pharma Co. Strongly Beats on Consensus Q2 Revenue and Earnings Estimates

Research Report
  ()
Paradigm Capital Inc. stated in a research report that Knight Therapeutics Inc. posted significantly better than expected operating and financial results in Q2/21 that greatly exceeded analysts' estimates. Meanwhile, insiders continue to add to their positions, and the company has filed a new NCIB allowing it to purchase up to 10% of the float during the next 12 months. read more >

Travere Posts Positive Topline Data in Phase 3 IgA Nephropathy Study, Shares Trade Higher

  ()
Travere Therapeutics shares traded 14% higher after the company reported positive interim results from its ongoing Phase 3 PROTECT study of sparsentan in treating IgA nephropathy, a chronic kidney disease that can lead to end-stage renal disease. read more >

Coverage Initiated on Developer of Treatment for Myelofibrosis, GvHD, COVID-19

Research Report
  ()
A BTIG report noted that CTI Biopharma's Pacritinib "has the potential to be a lead therapeutic in the myelofibrosis space and in additional indications that could provide material value to CTI and CTI's shares over time." read more >
News Update

Pharma Developer Licenses Patent for Treating Neuroendocrine Cancers from US Ivy League College

News Update
  ()
Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors. read more >

Fulcrum Shares Soar on Positive Interim Data in Phase 1 Sickle Cell Disease Study

  ()
Fulcrum Therapeutics shares rose 125% and set a new 52-week high after the company reported Q2/21 financial results and released positive interim results from its Phase 1 sickle cell disease trial. read more >

Cortexyme Expects to Release Positive Topline Data from Ph. 2/3 Alzheimer's Trial by Late Autumn

  ()
Shares of Cortexyme Inc. traded 47% higher to a new 52-week high after the company reported Q2/21 financial results and provided an update regarding its ongoing Alzheimer's and periodontal disease clinical trials. read more >
Showing Results: 1 to 25 of 101 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"GCX reported an impressive hit from a hole drilled on Carmacks."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"Drilling makes CBR a compelling lever in a looming fall gold price boom."
– Brien Lundin, Gold Newsletter (Jefferson Financial)